Population Pharmacokinetic Models of Oxypurinol in Adults: A Systematic Review
- 24 March 2026
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Drug Metabolism
- Vol. 27 (4) , 1-19
Abstract
Introduction: Allopurinol and its active metabolite, oxypurinol, reduce uric acid concentrations through xanthine oxidase inhibition by suppressing the conversion of hypoxanthine and xanthine. Oxypurinol plays a prominent role in allopurinol’s pharmacological activity due to its longer elimination half-life. Despite decades of clinical use, establishing an optimal dosing strategy to consistently achieve the target serum uric acid concentration lower than 0.36 mmol L-1 remains challenging. This review aimed to summarize the development of population pharmacokinetic modeling for oxypurinol and analyze factors influencing its pharmacokinetic variability. Methods: PubMed, Web of Science, and Scopus were systematically searched from database inception until January 2025, adhering to the PRISMA guideline. Studies were eligible if they involved oxypurinol population pharmacokinetic analyses in adults receiving allopurinol and employed nonlinear mixed-effects modeling Results: Eight studies met the inclusion criteria, mostly involving adult gout patients. Pharmacokinetic analyses of oxypurinol employed a one-compartment model, incorporating firstorder absorption and elimination, reporting clearance value of 0.60−1.74 L h-1 and volume of distribution 38.1−59.3 L. Covariates associated with oxypurinol clearance included creatinine clearance, body weight, normal fat mass, fat-free mass, ethnicity, genetic polymorphisms, and concomitant diuretics; whereas, total body weight was found as significant predictors for volume of distribution. Discussions: Reported values for oxypurinol clearance and volume of distribution varied across studies. The small sample sizes and underrepresentation of certain populations, particularly Asians, restrict the generalizability of these findings. Conclusion: Further research involving larger, more diverse cohorts is needed to refine therapeutic drug monitoring and identify potential covariates across different populations to optimize allopurinol therapy.Keywords
This publication has 83 references indexed in Scilit:
- Determinants of Achieving Serum Urate Goal with Treat‐to‐Target Urate‐Lowering Therapy in GoutArthritis & Rheumatology, 2023
- 2020 American College of Rheumatology Guideline for the Management of GoutArthritis Care & Research, 2020
- Pharmacokinetics and population pharmacokinetics in pediatric oncologyPediatric Blood & Cancer, 2019
- Genome‐Wide Association and Functional Studies Reveal Novel Pharmacological Mechanisms for AllopurinolClinical Pharmacology & Therapeutics, 2019
- 2017 ACR/ARHP Annual Meeting Abstract SupplementArthritis & Rheumatology, 2017
- Genome‐wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug responseClinical Pharmacology & Therapeutics, 2015
- Introduction to Population Pharmacokinetic / Pharmacodynamic Analysis with Nonlinear Mixed Effects Models2014
- Starting dose is a risk factor for allopurinol hypersensitivity syndrome: A proposed safe starting dose of allopurinolArthritis & Rheumatism, 2012
- Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairmentArthritis & Rheumatism, 2011
- Confirmatory analysis for phase III population pharmacokineticsPharmaceutical Statistics, 2011